Sanofi acquired Kymab, U.K. based drugmaker that develops monoclonal antibodies

In Jan 2021, Sanofi acquired Kymab, adding KY1005 to its pipeline, a human monoclonal antibody targeting key immune system. Kymab is a clinical stage biopharmaceutical company developing fully human monoclonal antibodies with a focus to treat immune-mediated diseases and immuno-oncology therapeutics. Sanofi is a dedicated company for its customers to support them in any health challenges. Sanofi is a global biopharmaceutical company focused on human health. They prevent illness with medicines, vaccines and innovative treatments to fight from diseases and suffering. Sanofi is transforming scientific innovations into healthcare solutions around the globe.

 This acquisition had resulted Sanofi having full rights to KY1005, a human monoclonal antibody that has a novel mechanism of action. KY1005 binds with OX40 ligand and has a potential to treat a large variety of inflammatory disorders and immune mediated diseases.

“The Kymab acquisition adds KY1005 to our dynamic pipeline, a potential first-in-class treatment for a range of immune and inflammatory diseases. The novel mechanism of action may provide treatment for patients with suboptimal responses to available therapies,” said Paul Hudson, Sanofi Chief Executive Officer. “We understand from our ongoing work in debilitating immunological diseases how critical it is to find the right treatment for each patient. We look forward to rapidly developing this investigational medicine